
Opinion|Videos|August 1, 2024
ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions
Author(s)Jason Porter, MD
Jason Porter, MD, provides concluding insights on the LAURA phase 3 trial, CHRYSALIS-2 study, TROPION-Lung05 trial, and CheckMate 9LA study, along with other notable findings from the ASCO 2024 conference.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- How do these four trials address the unmet needs of patients with NSCLC?
- After the presentation of advancements in NSCLC research at ASCO, how do you envision the future of personalized medicine in this disease?
- Please discuss any other data in NSCLC released at ASCO 2024 that you find noteworthy to share with colleagues.
- Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of NSCLC? What can we look forward to through the end of the year and beyond?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
2
Network Disconnection, Not Lesion Volume, Drives MS Cognition
3
Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer
4
Colorblind Devices, Longer-Wavelength Lasers Offer Safer Options for Darker Skin Tones: Ariella Kauvar, MD
5